Chronopharmacology of Lithium Preparations
Suggested citation:
Arushanyan EB. [Chronopharmacology of Lithium Preparations]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2017;(6):54-59. Russian
As shown by modern literature data, the time factor plays an important role in the pharmacodynamics of lithium used for the treatment of bipolar affective disorder. Its chronotropic properties may depend on the effect on the function of suprachiasmatic nuclei of the hypothalamus, as well as inhibition of glycogen synthase-3 kinase and the mobilization of the epiphyseal hormone melatonin.
Keywords lithium; bipolar affective disorder; melatonin
1. Arushanian EB. [Complex relationships of the suprachiasmatic nuclei with the pineal gland and striatum as a unitary system which regulates the behavioural circadian rhythmicity]. Zhurnal vysshei nervnoi deiatelnosti im. I.P. Pavlova [Neuroscience and Behavioral Physiology]. 1996;46(1):16-22. Russian. 2. Arushanian EB. Glavnaia mishen - khronopsikhofarmakologiia (k 20-letiiu nauchnogo poiska sotrudnikov kafedry farmakologii). Meditcinskii vestnik Severnogo Kavkaza [Medical news of the North Caucasus]. 2007;6:3-16. Russian. 3. Arushanian EB. Unikalnyi melatonin. Stavropol, 2007. 360 p. Russian. 4. Arushanian EB. Melatonin – universalnyi stabilizator psikhicheskoi deiatelnosti. Zhurnal vysshei nervnoi deiatelnosti im. I.P. Pavlova [Neuroscience and Behavioral Physiology]. 2011;61(6):645-59. Russian. 5. Arushanian EB. Mesto tcentralnykh apparatov upravleniia biologicheskimi ritmami v geneze psikhopatologii i deistvii psikhotropnykh sredstv. Hronopatologia i hronomedizina. In: Khronopatologiia i khronomeditcina. Moscow; 2012. p. 122-40. Russian. 6. Arushanian EB. Ogranichenie okislitelnogo stressa kak osnovnaia prichina universalnykh zashchitnykh svoistv melatonina. Eksperimentalnaia i klinicheskaia farmakologiia [Russian Journal of Experimental and Clinical Pharmacology]. 2012;75(5):44-9. Russian. 7. Arushanian EB, Ovanesov KB. [Role of pineal gland in pathogenesis of depression]. Zhurnal vysshei nervnoi deiatelnosti im. I.P. Pavlova [Neuroscience and Behavioral Physiology]. 1991;41:822-7. Russian. 8. Markova NA, Shvezova EF. [Stress-induced depression as a risk factor for Alzheimer`s disease: the role of glycogen synthase kinase-3]. Patogenez [Pathogenesis]. 2013;11(4):4-8. Russian. 9. Abe M, Herzog ED, Block GS. Lithium lengthens the circadian period of individual suprachiasmatic nucleus neurons. Neurorport. 2000;11:3261-4. 10. Abreu T, Braganca M. The bipolarity of light and dark: A review on bipolar disorder and circadian cycles. J. Affect. Disord. 2015;185:219-29. 11. Anderson G, Maes M. Oxidative/nitrosative stress and immuneinflammatory pathways in depression: treatment implications. Curr. Pharm. Res. 2014;20(23):3812-47. 12. Bellivier F, Geoffroy PA, Etan B. Sleep- and circadian rhythm-associated pathways as therapeutic targets in bipolar disorder. Expert. Opin. Ther. Targets. 2015;19(6):747-63. 13. Besing RC, Paul JR, Habitz M, et al. Circadian rhythmicity of active GSK3 isoforms modulates molecular clock gene rhythms in the suprachiasmatic nucleus. J. Biol. Rhythms. 2015;30(2):155-60. 14. Crofton EJ, Nenov MN, Zhang Y. Glycogen synthase kinase 3 beta alters anxiety-, depression-, and addiction-related behaviors and neuronal activity in the nucleus accumbens shell. Neuropharmacology. 2017;117:49-60. 15. Etan B, Dumaine A, Bellivier F. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum. Mol. Genet. 2012;21(18):4030-7. doi: 10.1093/hmg/dds227. 16. Fomaro M, McCarthy MJ, De Berardis D, et al. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study. Neuropsychiatry Dis. Treat. 2013;9:243-51. 17. Geoffroy PA, Curis E, Courtin C, et al. Lithium response in bipolar disorders and core clock genes expression. World J. Biol. Psychiatry. 2017;16:1-31. doi: 10.1080/15622975.2017.1282174 18. Geoffroy PA, Etan B, Franchi JA, et al. Melatonin and melatonin agonist as adjunctive treatment in bipolar disorders. Curr. Pharm. Des. 2015;21:3352-8. 19. Geoffroy PA, Samalin L, Lorca P, et al. Influence of lithium jn sleep and chronotypes in remitted patients with bipolar disorders J. Affect. Disord. 2016;204;32-39. 20. Gonzalez R. The relationship between bipolar disorder and biological rhythms. J. Clin. Psychiatry. 2014;75(4):323-31. 21. Iwahana E, Akiyama M, Miyakawa K, et al. Effect of lithium on the circadian rhythms of locomotor activity and glycogen synthase kinase-3 expression in the mouse suprachiasmatic nuclei. Eur. J. Neurosci. 2004;19(8):2281-7. 22. Jope RS, Roh MS. Glycogen synthase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr. Drug Targets. 2006;7(11):1421-34. 23. Kaladchibachi SA, Doble B, Anthonopoulos N, et al. Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium. J. Circadian. Rhythms. 2007;5:3-10. 24. Kinoshita C, Miyazaki K, Ishida N. Chronic stress affects PERIOD 2 expression through glycogen synthase kinase-3 phosphorylation in the central clock. Neuroreport. 2012;23(2):98-102. doi: 10.1097/WNR.0b013e32834e7ec2 25. Luca A, Calandia C, Luca M. GSK3 signalling and redox status in bipolar disorder: evidence from lithium efficacy. Oxid. Med. Cell Longev. 2016;30:547-550. doi: 10.1155/2016/3030547. 26. McClung CA. Role of the clock gene in bipolar disorder Cold. Spring Harb. Symp. Quant. Biol. 2007;72:637-44. doi: 10.1101/sqb.2007.72.031. 27. Milhiet V, Boudebesse C, Bellivier F, et al. Circadian abnormalities as markers of susceptibility in bipolar disorders. Front. Biosci. 2014;6:120-37. 28. Moreira J, Geoffroy PA. Lithium and bipolar disorder: Impacts from molecular to behavioural circadian rhythms. Chronobiol. Int. 2016;33(33):351-73. doi: 10.3109/07420528.2016.1151026. 29. Murray G, Harvey A. Circadian rhythms and sleep in bipolar disorder. Bipol. Disord. 2010;12(5):459-72. doi: 10.1111/j.1399-5618.2010.00843.x. 30. Nierenberg AA. Low-dose buspirone, melatonin and low-dose bupropion added to mood stabilizers for severe treatment-resistant bipolar depression. Psychother. Psychosom. 2009;78(6):391-3. doi: 10.1159/000235985. 31. Reiter RJ, Calvo JR, Karbownik KH. Melatonin and its relation to the immune system and inflammation. Ann. N.Y. Acad. Sci. 2000;917:376-86. 32. Seggie J, Westiuk ES, Grota L. Lithium and circadian patterns of metabolism in the retina, hypothalamus, pineal and serum. Prog. Neuropharmacol. Biol. Psychiatry. 1987;11(2-3):325-34. 33. Souza LG, Wilhelm EA, Bortrolatto CF, et al. The protective effect of melatonin against brain oxidative stress and hyperlocomotion in a rat model of mania induced by ouabain. Behav Brain Res. 2014 Sep 1;271:316-24. doi: 10.1016/j.bbr.2014.06.030. Epub 2014 Jun 21. 34. Valvassori SS, Dal-Pint GC, Resende WR, et al. Lithium and valproate act on the GSK-3β signaling pathway to reverse manic-like behavior in an animal model of mania induced by ouabain. Neuropharmacology. 2017 May 1;117:447-59. doi: 10.1016/j.neuropharm.2016.10.015. Epub 2016 Oct 24. 35. Valvassori SS, Rezin GT, Ferreira CL, et al. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J. Psychiatry Res. 2010;44(14):903-9.
Article Metrics
Metrics powered by PLOS ALM